ArticleFrontiers in immunology2026
Mesenchymal stem cell - derived extracellular vesicles modulate immune function in sepsis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe sepsis is characterized by dysregulated immune responses associated with high mortality. Both hyperinflammation and progressive immunosuppression contribute to poor outcomes, yet reliable biomarkers and effective immunomodulatory therapies remain limited. Extracellular vesicles derived from induced pluripotent stem cell-derived mesenchymal stem cells (iMSC-EVs) represent a promising cell-free therapeutic strategy, but their effects on immune dysfunction in human sepsis are poorly characterized. Methods: Fifty-three patients with surgical sepsis meeting Sepsis-3 criteria were prospectively enrolled. Sixty-day mortality was used to define the survivor (n=26) and non-survivor (n=27) groups. Logistic regression identified mediators independently associated with mortality and SOFA score. Cytokine profiles in plasma and media were quantified by ELISA. Peripheral blood mononuclear cells (PBMCs) were isolated and treated with LPS, iMSC-EVs or both. Apoptosis, caspase-3 expression, and acute-phase markers (CRP, SAA) were assessed. Results: Increased age, cancer diagnosis and SOFA score were associated with mortality. Non-survivors exhibited significantly elevated IL-10, MCP-1, and IL-10/TNF-α ratio, with a lower IL-6/IL-10 ratio. IL-10 (OR = 1.12), MCP-1 (OR = 1.05), and IL-10/TNF-α ratio (OR = 6.61) independently predicted 60-day mortality. LPS-stimulated PBMCs from non-survivors showed a distinct pattern of cytokine responses compared to survivors. iMSC-EV treatment attenuated LPS-induced inflammation, reduced the IL-10/TNF-α ratio, decreased apoptosis and caspase-3 activation, and modulated CRP and SAA in a context-dependent manner. Conclusions: Patient characteristics and cytokine levels were associated with 60-day sepsis mortality and reflect immunosuppression severity. iMSC-EVs exert immunomodulatory and cytoprotective effects on septic patient-derived PBMCs, supporting their potential as a cell-free therapeutic strategy for restoring immune homeostasis in sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.